Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Phase 1/2

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

NCT05434156 · tracked via the Priya Life Science UK tracker
Sponsor
Eleusis Therapeutics
Phase
Phase 1/2
Started
2022-10-27
Last updated
2025-02-19

Condition(s) studied

Healthy VolunteersMajor Depressive DisorderDepression

Investigational drug(s) / intervention(s)

ELE-101ELE-101 Placebo

ELE-101: ELE-101 solution for intravenous infusion

ELE-101 Placebo: ELE-101 placebo matching solution for intravenous infusion

Study summary

A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy male or female participants aged 18 to 65 years, inclusive. * Participants have a body mass index (BMI) of 18 to 35 kg/m2, inclusive. * Participants are able and willing to give written informed consent, adhere to the compliance terms during participation in the study, undergo the examinations and testing set forth in the study Protocol and clearly and reliably communicate their subjective symptoms to the Investigator. * Part 2 Only: Patient has a diagnosis of MDD and is not on antidepressant medication. Exclusion Criteria: * Current, or history (within the last 6 months) of, alcohol or substance use disorder. * Use of pharmacological compounds for psychiatric or neurological conditions acting on the CNS within 30 days or 5 half-lives (whichever is longer) prior to Screening. * Current or clinically relevant history of schizophrenia, psychotic, bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder or panic disorder. * In first-degree relatives, a history of schizophrenia, psychosis, bipolar disorder, delusional disorder, paranoid personality disorder or schizoaffective disorder. * History of a diagnosis of Hallucinogen Persistent Perceptual Disorder (HPPD). * Significant suicide risk. * Other personal circumstances and behavior that is incompatible with establishment of rapport or safe exposure to psilocin, as judged by the Investigator. * Part 1 Only: Ongoing current MDD, or history of MDD within the last year.

Primary outcome measure(s)

  • Part 1: Percentage of participants with at least one safety event — Baseline up to Day 8
    * Safety will be evaluated by the monitoring of adverse events (AEs), vital signs, blood pressure, heart rate, pulse oximetry, electrocardiogram (ECG) evaluations, clinical laboratory assessments, injection site reactions and physical examination findings. * Suicidal ideation and behavior will be evaluated using the Columbia-Suicide Severity Rating Scale (C-SSRS). * Percentage of participants who experience at least one treatment-emergent adverse event (TEAE) will be captured. * Tolerability will be measured using the SDI questionnaires to rate the intensity of the psychedelic experience alongside recordings of anticipated adverse effects such as nausea and headache.
  • Part 2: Subjective Drug Intensity Ratings — pre-dose and at multiple time-points up to 24 hours post-dose
    \- The SDI questionnaire will be used to rate the real-time intensity of the psychedelic experience

Trial sites (2)

FacilityCityRegionStatus
MAC Clinical Research Liverpool United Kingdom
MAC Clinical Research Manchester United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05434156 on ClinicalTrials.gov ↗ ← All trials in the UK